Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7863498 | 0.98 | TAAR1 (0.50) | TAAR1HTR2ATRPA1TSHRCHRNB2 | |
| SCHEMBL12949533 | 0.83 | HRH1 (0.56) | TAAR1HTR2ATRPA1TSHRHRH1 | |
| SCHEMBL2010047 | 0.82 | TRPA1 (0.52) | TAAR1HTR2ATRPA1TSHRHRH1 | |
| SCHEMBL1344877 | 0.81 | TSHR (0.50) | TAAR1HTR2ATRPA1TSHRHRH1 | |
| Hydrochloric Acid SCHEMBL8171553 | 0.81 | HRH1 (0.54) | TAAR1HTR2ATRPA1TSHRHRH1 | |
| SCHEMBL7336616 | 0.79 | HRH1 (0.59) | TAAR1HTR2ATRPA1TSHRHRH1 | |
| SCHEMBL28036801 | 0.78 | ESR2 (0.48) | TAAR1 | |
| SCHEMBL10600837 | 0.78 | ESR1 (0.63) | TAAR1TSHRSLC6A2SLC6A3 | |
| SCHEMBL23199874 | 0.77 | TSHR (0.52) | TAAR1HTR2ATRPA1TSHR | |
| SCHEMBL3516304 | 0.77 | TAAR1 (0.52) | TAAR1HTR2ACHRNB2CHRNA4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021060277-A1 | AMINATING AGENT AND METHOD FOR PRODUCING AMINATED PRODUCT | ＡＧＣ株式会社 | 2021-04-01 | — | — | WO | disclosed |
| CN-103969952-B | New compound and its manufacture method, acid agent, anti-corrosion agent composition and Resist patterns forming method | 东京应化工业株式会社 | 2017-08-01 | — | — | CN | disclosed |
| CN-106986792-A | New compound and its manufacture method, acid agent, anti-corrosion agent composition and Resist patterns forming method | 东京应化工业株式会社 | 2017-07-28 | — | — | CN | disclosed |
| CN-103635452-B | The reduced coenzyme Q 10 crystal of excellent in stability | 株式会社钟化 | 2017-03-15 | — | — | CN | disclosed |
| CN-103025881-B | Process for preparing fat-soluble physiologically active substance | KANEKA CORP. (JP) | 2016-03-30 | — | — | CN | disclosed |
| CN-102656133-B | Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same | KANEKA CORP | 2015-04-15 | — | — | CN | disclosed |
| US-20140371065-A1 | Fungicidal Pyrimidine Compounds | BASF SE (DE) | 2014-12-18 | — | — | US | disclosed |
| CN-102381948-B | Method of stabilizing reduced coenzyme Q10 | KANEKA CORP. (JP) | 2014-10-01 | — | — | CN | disclosed |
| CN-101842340-B | Method for production of reduced coenzyme Q10 using water-containing organic solvent | KANEKA CORP | 2014-08-13 | — | — | CN | disclosed |
| CN-103635452-A | Reduced coenzyme Q10 crystal having excellent stability | KANEKA CORP | 2014-03-12 | — | — | CN | disclosed |
| CN-1525951-A | Reduced coenzyme Q10Method for stabilization of (3) and method for acid crystallization | ��Ԩ��ѧ��ҵ��ʽ���� | 2004-09-01 | — | — | CN | disclosed |
| CN-1140500-C | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | ��˹��ŵ�� | 2004-03-03 | — | — | CN | disclosed |
| CN-1094487-C | Oxime derivative and fungicide containing the same as active ingredient | SHIONOGI & CO (JP) | 2002-11-20 | — | — | CN | disclosed |
| CN-1085666-C | 6-aryl pyrido (2,3-d) pyrimidines and naphthyridines for inhibiting protein tyrosine kinase medicated cellular proliferation | WARNER LAMBERT CO (US) | 2002-05-29 | — | — | CN | disclosed |
| CN-1268112-A | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives thereof | NOVARTIS AG (CH) | 2000-09-27 | — | — | CN | disclosed |
| CN-1169726-A | 6-aryl pyrido (2,3-d) pyrimidines and naphthyridines for inhibiting protein tyrosine kinase medicated cellular proliferation | WARNER LAMBERT CO (US) | 1998-01-07 | — | — | CN | disclosed |
| CN-1144524-A | Oxime derivative and fungicide containing the same as active ingredient | SHIONOGI & CO (JP) | 1997-03-05 | — | — | CN | disclosed |
| EP-0219961-B1 | IRREVERSIBLE DOPAMINE-B-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4760089-A | Benzonitrile derivative; enzyme inhibitor | SMITHKLINE BECKMAN CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0219961-A1 | Irreversible dopamine-B-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371065-A1 | Fungicidal Pyrimidine Compounds | DPM1, DPYD, TYMP | TAAR1 3763/4885HTR2A 4506/4885TRPA1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.